Introduction {#sec1}
============

*Pseudomonas aeruginosa* is one of the most virulent opportunistic pathogens, being responsible for various diseases such as acute infections of lungs and burned skin that can lead to septicemia more particularly in immunocompromized patients, or broncho-alveolar colonization in cystic fibrosis sufferers. *P. aeruginosa* has been classified in 2017 as critical by the WHO in the top three lists of antibiotic resistant bacteria ([@ref45]). *P. aeruginosa* has developed various pathogenicity strategies among which protein secretion or protein delivery into target cells is key. Indeed, this pathogen possesses five of the six secretion systems so far identified among Gram-negative bacteria, if we exclude the T9SS (type IX secretion system) restricted to one phylum, and remarkably in several copies for most of them ([@ref7]).

The type VI secretion system (T6SS) was first discovered in the context of eukaryotic host infection ([@ref30]; [@ref34]) and later during bacterial competition ([@ref16]), which seems to be its primary function ([@ref12]). The T6SS confers a fitness advantage (1) in environmental niches against rival bacteria (inter- and intraspecies competitiveness have been described) and (2) in the eukaryotic host towards commensal bacteria ([@ref12]). Indeed, recent studies have highlighted a novel role for T6SS-dependent antibacterial responses in interbacterial competition in the mammalian gut ([@ref15]; [@ref39]), suggesting that T6SSs may be important not only in shaping microbial community composition but also in governing interactions between the microbiota and invading pathogens. Interestingly, several T6SSs are also known to target both cell type genus such as the T6SS of *Vibrio cholera* ([@ref34]; [@ref27]) and *P. aeruginosa* ([@ref40]) ([@ref35]). Even more remarkably, three T6SS effectors of *P. aeruginosa*, namely, PldA (also called Tle5a), PldB (Tle5b), and TplE (Tle4) ([@ref21], [@ref20]) have been called "trans-kingdom effectors" since these toxins can target both prokaryotic and eukaryotic cells ([@ref6]). Indeed, toxins are usually directed against eukaryotic cells (like AB toxins or RTX pore-forming toxins) or against rival bacteria (like bacteriocins).

The T6SS functions as a dynamic contractile phage tail-like structure anchored in the bacterial cell envelope that delivers effector proteins directly into the target cell in a one-step manner. T6SS includes a contractile sheath that cover a nanotube of stacked Hcp topped with a membrane-puncturing spike made of VgrG and PAAR (proline-alanine-alanine-arginine repeat) proteins ([@ref3]). The sheath can contract and inject the arrow loaded with effectors into the target cell. Characterizing the repertoire of effectors delivered by the T6SS has highlighted a great diversity in terms of effector activities, host cell targets, and mode of recruitment by the T6SS machinery. In brief, there are two broad effector categories: the "specialized" effectors fused to components of the machinery (evolved VgrG, evolved PAAR, and evolved Hcp have been described so far) and the "cargo" effectors ([@ref12]). The later are addressed to the T6SS machinery by binding directly one of the arrow components (VgrG, PAAR, and Hcp) or by being targeted through cytoplasmic adaptor proteins also called chaperones. To date, three families of adaptor have been described, the first one harboring a DUF4123 ([@ref29]; [@ref36]; [@ref25]; [@ref42]), the second a DUF1795 ([@ref1]; [@ref44]), and the third one a DUF2169 ([@ref8]). In line with this, many effector-encoding genes are found in close proximity to *vgrG*, *hcp*, and *paar* or adaptor genes. Finally to protect themselves from self-intoxication or from antibacterial toxins injected by neighboring sibling cells, bacteria always synthesize immunity proteins, which are encoded by adjacent genes ([@ref5]).

*P. aeruginosa* encodes three distinct T6SS loci, H1- to H3-T6SS. While H1-T6SS has only been involved in antibacterial activity so far ([@ref38]; [@ref24]), H2-T6SS and H3-T6SS can target both bacterial and eukaryotic cells possessing even as said earlier trans-kingdom effectors ([@ref40], [@ref37]; [@ref35]; [@ref21], [@ref20]; [@ref9]). We discovered the anti-eukaryotic function of the H2-T6SS machinery that promotes the uptake of *P. aeruginosa* by non-phagocytic cells ([@ref40]). The two phospholipases D mentioned earlier, PldA (Tle5a) and PldB (Tle5b), delivered, respectively, by H2-T6SS and H3-T6SS machineries participate in the host kinase pathway hijacking that facilitates further entry of *P. aeruginosa* ([@ref21]). The evolved VgrG2b effector ([@ref37]) is delivered by H2-T6SS into epithelial cells where it targets the γ-tubulin ring complex, a microtubule-nucleating multiprotein complex to promote a microtubule-dependent internalization of *P. aeruginosa*. Finally TplE (Tle4), which is secreted by the H2-T6SS machinery, promotes autophagy in epithelial cells once localized to the endoplasmic reticulum ([@ref20]). Interestingly, PldA (Tle5a), PldB (Tle5b), and TplE (Tle4) have also been identified as antibacterial phospholipases of the Tle (type VI lipase effectors) family ([@ref35]). They work by affecting membrane integrity of the rival bacteria ([@ref35]; [@ref21], [@ref20]). More precisely, PldA degrades the major constituent of bacterial membranes, the phosphatidylethanolamine ([@ref35]).

In the present study, we have discovered a novel antibacterial toxin, Tle3, and its cognate immunity, Tli3, whose genes are encoded downstream of *vrgG2b*. By characterizing the secretion mechanism of Tle3 by H2-T6SS, we showed that it requires Tla3, a cytoplasmic adaptor of a unique family, to be targeted to the VgrG2b spike. Interestingly, we also found that the C-terminal extension of VgrG2b is toxic towards *Escherichia coli* making VgrG2b a new trans-kingdom effector of *P. aeruginosa*.

Materials and Methods {#sec2}
=====================

Bacterial Strains, Growth Conditions, and Plasmid Construction {#sec3}
--------------------------------------------------------------

All *P. aeruginosa* and *E. coli* strains used in this study are described in [Supplementary Table S1](#SM1){ref-type="supplementary-material"}. Briefly, the *E. coli* K-12 DH5α and CC118λPir were used for cloning procedures. The BL21(DE3)pLysS and BTH101 were used for protein production and BACTH analyses, respectively. Strains were grown in LB or in TSB medium (for *P. aeruginosa*) at 37 or 30°C. Specific growth conditions are specified in the text when necessary. Recombinant plasmids were introduced into *P. aeruginosa* by triparental mating using the conjugative properties of the helper plasmid pRK2013 ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}). Plasmids were maintained by the addition of ampicillin (50 μg/ml), kanamycin (50 μg/ml), chloramphenicol (30 μg/ml), streptomycin (30 μg/ml for *E. coli* and 2,000 μg/ml for *P. aeruginosa*), or gentamicin (30 μg/ml for *E. coli* and 115 μg/ml for *P. aeruginosa*). Expression of genes from pT7 in BL21(DE3)pLysS was blocked with 0.4% of glucose and induced in exponential phase (OD~600~ = 0.4--0.6) for 3 h with 1 mM of IPTG. Cloning procedures were described in [@ref37]. The plasmids used and constructed are described in [Supplementary Table S1](#SM1){ref-type="supplementary-material"}, the list of oligonucleotides (synthesized by Eurogentec or IDT) is given in [Supplementary Table S2](#SM1){ref-type="supplementary-material"}.

Cloning Procedures for *P. aeruginosa* Mutants {#sec4}
----------------------------------------------

To generate *P. aeruginosa* mutants, 500 bp upstream and 500 bp downstream of the gene to be deleted were amplified by overlapping PCR with Q5 high fidelity DNA polymerase (NEB) using primers listed in [Supplementary Table S1](#SM1){ref-type="supplementary-material"}. The PCR product was cloned in pKNG101 suicide vector by one-step sequence and ligation-independent cloning (SLIC) ([@ref19]), which was then sequenced. pKNG101 derivatives, maintained in the *E. coli* CC118λpir strain, were mobilized in *P. aeruginosa* strains. The mutants, in which the double recombination events occurred, were confirmed by PCR analysis.

Heterologous Toxicity Assays {#sec5}
----------------------------

*E. coli* BL21(DE3)pLysS containing plasmids producing cytoplasmic or periplasmic targeted proteins were grown overnight at 37°C in LB with 0.4% of glucose. About 10 μl drops of bacterial suspensions serially diluted were spotted onto LB agar plates containing 0.1 mM IPTG or 0.4% glucose and cells were grown for 16 h at 37°C.

Bacterial Two-Hybrid Assay {#sec6}
--------------------------

Protein-protein interactions were assessed with the adenylate cyclase-based two-hybrid technique using protocols published previously ([@ref22]; [@ref4]). Briefly, the proteins to be tested were fused to the isolated T18 and T25 catalytic domains of the *Bordetella* adenylate cyclase. After introduction of the two plasmids producing the fusion proteins into the reporter BTH101 strain, plates were incubated at 30°C for 24 h. Three independent colonies for each transformation were inoculated into 600 μl of LB medium supplemented with ampicillin (50 μg/ml), kanamycin (50 μg/ml), and IPTG (0.5 mM). After overnight growth at 30°C, 5 μl of each culture was spotted onto LB agar plates supplemented with ampicillin, kanamycin, IPTG, and 5-bromo-4-chloro-3-indonyl-[d]{.smallcaps}-galactopyrannoside (X-gal, 40 μg/ml) and incubated for 16 h at 30°C.

Protein Purification by Affinity Chromatography {#sec7}
-----------------------------------------------

*E. coli* BL21(DE3)plysS cells carrying the pRSFDUET-1 and pETDUET-1 derivatives were grown at 37°C in LB to an OD~600~\~0.5 and the expression of the PA0262, PA0261, PA0260, or PA0259 genes was induced with IPTG (1 mM) for 3 h at 37°C. Cells were harvested by centrifugation at 1,914 × *g* for 30 min at 4°C. The cell pellet was resuspended in Tris--HCl 50 mM pH 8.0, NaCl 150 mM, Triton X-100 0.1%, lysozyme 0.5 mg/ml, and EDTA 1 mM and stored at −80°C. Cells were supplemented with DNase (20 μg/ml), MgCl~2~, and phenylmethylsulfonyl fluoride 1 mM and cells were lysed by three passages at the Emulsiflex-C5 (Avestin), and lysates were clarified by centrifugation at 16,000 × *g* for 30 min. The supernatant was loaded onto a 5-ml StrepTrap HP (GE Healthcare) column and then washed with 50 mM Tris-HCl pH 8.0, 150 mM NaCl at 4°C. The fusion protein was eluted in the affinity buffer supplemented with 2.5 mM desthiobiotin. Peak fractions were pooled and loaded onto a Superose 200 10/300 column (GE Healthcare) equilibrated in 50 mM Tris-HCl pH 8.0, 50 mM NaCl.

Fractionation of *P. aeruginosa* {#sec8}
--------------------------------

Fractionation of cells into spheroplasts (cytoplasm and membranes) and periplasmic fractions were done as previously described ([@ref18]). Proteins corresponding to the cytoplasm and periplasm fractions or to insoluble material were resuspended in loading buffer.

Protein Secretion {#sec9}
-----------------

*P. aeruginosa* strains were grown at 25°C in TBS for 24 h. Cells corresponding to 10 U DO~600~ and extracellular medium were separated by centrifugation at 2,000 × *g* for 10 min at room temperature. 2/3 of the supernatants were collected and centrifuged at 13,000 × *g* for 5 min at room temperature. Proteins contained in the supernatant were precipitated with tricholoro-acetic acid (TCA, 15%) for 3 h at 4°C. Samples were centrifuged at 13,000 × *g* for 30 min at 4°C, pellets washed with 90% acetone, and resuspended in loading buffer.

SDS-PAGE and Western-Blot {#sec10}
-------------------------

Protein samples derived from equivalent amounts of culture (i.e., optical density equivalents) resuspended in loading buffer were boiled and separated by SDS-PAGE. Proteins were then stained by Coomassie-blue or immunodetected as described before ([@ref37]) using primary polyclonal antibodies directed against His6 epitope-tag (Penta His, Qiagen, dilution 1:1,000), V5 epitope-tag (Bethyl Laboratories, dilution 1:1,000), Strep epitope-tag (IBA StrepMAB Classic, dilution 1:000), DsbA (kindly gifted by K. E. Jaeger -- university of Heinrich-Heine, dilution 1:25,000), or monoclonal antibodies directed against EF-Tu (Hycult-biotech, dilution 1:20,000), XcpY (laboratory collection, dilution 1:5,000), and TolB (laboratory collection, dilution 1:500). Peroxidase-conjugated anti-Mouse or anti-Rabbit IgGs (Sigma, dilution 1:5,000) were used as secondary antibodies. Nitrocellulose membranes were revealed with homemade enhanced chemiluminescence and were scanned using ImageQuant LAS4000 analysis software (GE Healthcare Life sciences).

Protein samples equivalent to 0.1 OD~600~ units were loaded for whole cell and spheroplasts analysis while protein samples equivalent to 0.2 OD~600~ units were used for cytoplasm or periplasm analysis and protein samples equivalent to 1 OD~600~ units were used for extracellular medium analysis.

Bacterial Competition Assays {#sec11}
----------------------------

Intraspecific competition assays between *P. aeruginosa* strains were performed as previously described ([@ref21]) with modifications. The prey cells carry pJN105 vector (Gm^R^) to allow counterselection. Overnight cultures of *P. aeruginosa* attacker and prey cells were mixed in a 10:1 (attacker:prey) ratio and harvested by centrifugation at 3,724 × *g* for 5 min. The pellet was resuspended in 200 μl of PBS 1X and spotted onto 0.45-μm nitrocellulose membranes overlaid on a 1% bactoagar plate. After 24 h of incubation at 37°C, cells were resuspended in 2 ml of PBS 1X, normalized to an OD~600nm~ of 0.5, and 10 μl of bacterial serially diluted (10^−1^ to 10^−6^) were spotted onto selective LB agar plates containing gentamicin (125 μg/ml). Significant growth difference of the prey bacteria for each competition assay was computed by one-way ANOVA (Stat Plus) and unpaired Student's Test (Excel).

Results {#sec12}
=======

Tle3 Is a Novel Antibacterial Toxin of *P. aeruginosa* {#sec13}
------------------------------------------------------

The analysis of the *vgrG2b* genetic environment revealed the presence of the PA0260 gene encoding a protein with a α/β hydrolase domain (PF00561) and a putative Ser-Asp-His catalytic triad used by various esterase enzymes and has thus been classified in the Tle3 family of antibacterial Tle toxins ([Figure 1A](#fig1){ref-type="fig"}; [@ref35]). The immunities of Tle proteins, which are lipolytic toxins active in the periplasm of the prey bacterium, are localized in or exposed to the periplasm where they neutralize the cognate toxin ([@ref35]; [@ref21], [@ref20]; [@ref14]). The two genes surrounding *tle3*, PA0259 and PA0261, are good candidates as Tle3 immunity. Indeed, sequence comparisons of PA0259 and PA0261 showed that PA0261 is homologous to Tsi6, the immunity protein of a H1-T6SS effector called Tse6, and PA0259 to TplEi (Tli4), the immunity of TlpE (Tle4), a H2-T6SS effector ([@ref26]; [@ref20]). We used the SignalP 4.1 server ([@ref32]) to predict the cellular localization of the two immunity candidates. While a Sec signal sequence is predicted at the N-terminal extremity of PA0261, the analysis of the PA0259 sequence did not reveal any. However, three upstream ATG can be found in frame with the annotated ATG of PA0259 ([Supplementary Figure S1](#SM1){ref-type="supplementary-material"}). The sequence of the proteins synthesized from the two first ATG (ATG~1~ and ATG~2~) presents then a N-terminal signal peptide, while the protein synthesized from the last codon (ATG~3~) does not. Moreover, a ribosome-binding sequence (RBS) can be found only upstream of ATG~1~ and with a significant Kolaskar score that indicates a strong probability to be used as an initiation codon ([@ref23]). Altogether, these data tend to indicate an incorrect annotation of the start codon of PA0259 and that ATG~1~ should be considered for the initiation of PA0259 translation. Such a correction has been already seen for Tli5 (PA3488) the immunity protein of PldA (Tle5a) of *P. aeruginosa* ([@ref35]). In conclusion of this *in silico* analysis, the two putative immunities may harbor a Sec signal peptide that suggests a periplasmic localization in agreement with Tle3 activity in this compartment.

![**(A)** *vgrG2b* island organization. The genes are labeled with the given name (i.e., *hcp2b*) and are indicated by their annotation number (e.g., PA0263). The Sec signal peptide of Tli3 (PA0261) and the two DUF2875 of Tla3 (PA0259) are represented with stripped boxes. **(B)** The Tle3 periplasmic toxicity is counteracted by Tli3 (PA0261). Serial dilutions (from non-diluted to 10^−7^) of normalized cultures of *E. coli* BL21(DE3)pLysS producing the wild-type Tle3 in the cytoplasm, called Tle3^c^ (from pVT1, a pETDuet-1 derivative) or in the periplasm, called Tle3^p^ \[from pSBC81, a pET22b(+) derivative yielding a fusion of Tle3 with a Sec signal peptide\] were spotted on LB agar plates supplemented (left panel) with 0.4% glucose or (right panel) with 0.1 mM IPTG. Glucose and IPTG allow respectively repression and induction of the gene encoding the T7 RNA polymerase. When indicated Tli3 (PA0261) or Tla3 (PA0259) were produced in the periplasm from pVT8, pSBC107 and pVT9, respectively, pRSFDuet-1 derivatives. Line 1: pET22b(+) and pRSFDuet-1, line 2: pVT1 and pRSFDuet-1, line 3: pSBC81 and pRSFDuet-1, line 4: pSBC81 and pVT8, line 5: pSBC81 and pVT9, line 6: pVT8 and pET22b(+), line 7: pVT9 and pET22b(+), and line 8: pSBC107 is a pRSFDuet-1 derivative producing Tli3 (PA0261) and Tle3^p^ from the same transcript.](fmicb-10-01218-g001){#fig1}

To demonstrate the antibacterial activity of Tle3 and to identify its immunity protein, we developed a heterologous toxicity assay in *E. coli* on the basis that Tle3 should be toxic when produced in the periplasm of *E. coli* and that it should be counteracted by the co-production of its immunity protein. In order to artificially address Tle3 to the periplasm of *E. coli* the *tle3* sequence has been cloned in frame with the sequence coding the PelB signal peptide on the pET22b vector under a P~T7~ promoter. PA0259 from ATG~1~ and PA0261 were respectively cloned in pRSF-DUET, a higher copy-number vector, to allow a maximal co-expression with *ss-tle3* in the *E. coli* BL21(DE3) pLysS strain. The correct production and localization of all the recombinant proteins in *E. coli* has been verified by western blot after cell fractionation ([Supplementary Figure S2](#SM1){ref-type="supplementary-material"}). The results presented in [Figure 1B](#fig1){ref-type="fig"} indicate that whereas the cytoplasmic production of Tle3 was not toxic, Tle3 targeting to the periplasm led to *E. coli* killing. Moreover, while PA0259 had no effect, the coproduction of PA0261 in the periplasm protected the cells against the toxicity of Tle3. We verified that the sole overproduction of PA0259 and PA0261 was not toxic to *E. coli*. As PA0261 neutralized Tle3 toxicity, we called it "Tli3" for Type VI lipase immunity ([Figure 1A](#fig1){ref-type="fig"}). During this study, we observed that the protection conferred by Tli3 coproduction could be sometimes partial and we solved this issue by cloning in tandem *tli3* and *tle3* on the same plasmid like they are organized on *P. aeruginosa* genome ([Figure 1B](#fig1){ref-type="fig"}, line 8). The importance of this genetic link is the proof of the close connection between these two proteins as a pair of toxin-antitoxin.

Tli3 (PA0261) Is the Immunity Protein of Tle3 {#sec14}
---------------------------------------------

As the immunities bind specifically their effector, which is suggested by the release of Tle3 toxicity by Tli3, we tested the physical interaction between both proteins by co-purification with affinity chromatography ([Figure 2A](#fig2){ref-type="fig"} and [Supplementary Figure S6](#SM1){ref-type="supplementary-material"}). A cytoplasmic Strep-tagged version of Tli3 was engineered by fusing the tag to the mature domain of Tli3, lacking its signal peptide. The recombinant protein was coproduced in *E. coli* BL21(DE3) pLysS with the cytoplasmic His~10~-tagged Tle3. The bacterial lysate was loaded to a StrepTactin matrix (see section "Materials and Methods"), and Tli3^C^~Strep~ was eluted with desthiobiotin. The presence of Tle3^C^~His~ was controlled in the elution fraction with anti-His antibodies. As showed in [Figure 2A](#fig2){ref-type="fig"} and [Supplementary Figure S6](#SM1){ref-type="supplementary-material"}, Tle3^C^~His~ was found in the eluted fraction only upon coproduction with Tli3^C^~Strep~ (left panel). Indeed when produced alone in *E. coli*, Tle3^C^~His~ was not purified by affinity chromatography (right panel). As expected for an immunity protein, Tli3 directly interacts with Tle3.

![**(A)** Tli3 (PA0261) interacts with Tle3. Copurification assay on StrepTactin column of Tli3c~Strep~ with Tle3c10~His~ produced in *E. coli* BL21(DE3)pLysS produced from pBB26 and pVT1 respectively. The unbound (U) and eluted (E) fractions were collected and subjected to SDS-PAGE (10.5%) and Western blot analyses using anti-His antibody (Upper) and anti-streptavidin antibody (Lower). The position of the proteins and the molecular mass markers (in kDa) are indicated. **(B)** Tli3 (PA0261) is a periplasmic protein in *P. aeruginosa*. Cells of *P. aeruginosa* PAO1 tli3~V5~ were subjected to fractionation and immunoblotting using antibodies directed against the V5 tag, XcpY and DsbA. XcpY and DsbA were used as membrane and periplasmic controls, respectively. T, whole cell; C, cytoplasm; Mb, total membrane; P, periplasm. The position of the proteins and the molecular mass markers (in kDa) are indicated.](fmicb-10-01218-g002){#fig2}

To go further into Tli3 characterization, we chose to determine its cellular localization in *P. aeruginosa*. All the immunity proteins identified so far for Tle proteins are localized in the periplasm or associated to the periplasmic side of the outer membrane ([@ref35]; [@ref21], [@ref20]; [@ref14]) in order to counteract their cognate toxin. A chromosomally encoded Tli3~V5~ translational fusion was engineered in order to specifically immunodetect the protein in *P. aeruginosa* ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}). After fractionation of *P. aeruginosa* ([Figure 2B](#fig2){ref-type="fig"}), Tli3 was readily observed in the same fraction as DsbA that catalyzes intrachain disulfide bond formation as peptides emerge into the periplasm. This indicates a periplasmic localization for Tli3 in *P. aeruginosa* in agreement with the presence of a Sec signal peptide and our working hypothesis suggesting an immunity function.

Tle3 Protein-Protein Interaction Network {#sec15}
----------------------------------------

To further characterize Tle3, we performed a bacterial two-hybrid (BACTH) assay with the other gene products of the *vgrG2b* operon hypothesizing that a genetic link could reflect protein-protein interaction. The sequences coding PA0259 and Tli3 (PA0261) after their signal sequences and Tle3 were cloned downstream and upstream the T18 or T25 domains of the *Bordetella adenylate* cyclase. Because of the high molecular weight of VgrG2b and since the interaction of another Tle with a VgrG in entero-aggregative *E. coli* (EAEC) was previously delimitated to the C-terminal domain of VgrG ([@ref14]), we cloned the sequences encoding the C-terminal extension (domains 1, 2, and 3) and a truncated version harboring only the DUF2345 and the transthyretin-like (TTR) domains (domains 1 and 2) of VgrG2b downstream the T18 and T25 domains ([Figure 3A](#fig3){ref-type="fig"}).

![**(A)** Tla3 (PA0259) interacts with the Tle3 toxin and with VgrG2b. Domain organization of VgrG2b, Tle3, and Tla3 (PA0259). The first 581 residues of VgrG2b carry the VgrG domain homologous to gp27 and gp5 phage tail proteins and consisting of three sub-domains. This is followed by the C-terminal extension, composed of a conserved domain of uncharacterized proteins (DUF2345, PF10106) (2bCt1), a TTR (transthyretin-like region) (2bCt2), and a putative zinc-dependent metallopeptidase pattern (LFIHEMTHVW signature, PS00142) (2bCt3). Tle3 architecture consists of an α,β hydrolase fold domain (Tle3~D1~) followed by a DUF3274 (Tle3~D2~), Tla3 of a tandem of DUF2875 (Tla3~D1~ and Tla3~D2~). **(B--D)** Bacterial two-hybrid assay. BTH101 reporter cells producing the indicated proteins or domains fused to the T18 or T25 domain of the *Bordetella* adenylate cyclase were spotted on X-gal indicator plates. The blue color of the colony reflects the interaction between the two proteins. TolB and Pal are two proteins known to interact but unrelated to the T6SS. The experiment was performed in triplicate and a representative result is shown.](fmicb-10-01218-g003){#fig3}

Unexpectedly, the sole interaction revealed by the BACTH assay for Tle3 was with PA0259 ([Figure 3B](#fig3){ref-type="fig"}) since only the T18/T25-Tle3 and T18/T25-PA0259 fusion proteins coproduction activated the expression of the reporter gene. This assay did not confirm the interaction between Tle3 and Tli3 observed by copurification and did not evidence an interaction with VgrG2b. Interestingly, Tle3 and PA0259 did not interact anymore when they were fused upstream the T18 and T25 domains suggesting that both proteins interact *via* their C-terminal domains ([Supplementary Figure S3A](#SM1){ref-type="supplementary-material"}). To go further in characterizing the interaction between Tle3 and PA0259, we constructed truncated variants taking into account their domain organization ([Figure 3A](#fig3){ref-type="fig"}). We further delimitated the interacting domain of Tle3 to its extreme C-terminus (the DUF3274 domain) since only the truncated T18-Tle3D2 construct still interacts with T25-PA0259 ([Figure 3C](#fig3){ref-type="fig"}). We did not find the domain of interaction within PA0259 as none of the DUF2875 domains alone interacts with Tle3 or this may suggest that both of them are required for the interaction ([Figure 3C](#fig3){ref-type="fig"}).

Next, we took advantage of all the constructs we made to test other interactions. The BACTH assay also showed that PA0259 interacts with both forms of the VgrG2b C-terminal extension ([Figure 3B](#fig3){ref-type="fig"}). The domain of interaction on VgrG2b is thus at least constituted by the DUF2345 and TTR domains. We also observed that PA0259 at least dimerizes since all the PA0259 constructs interact with each other whatever the orientation of PA0259 ([Figures 3B](#fig3){ref-type="fig"},[D](#fig3){ref-type="fig"}; [Supplementary Figure S3B](#SM1){ref-type="supplementary-material"}). VgrG2b and Tli3 (PA0261) are also able to homomultimerize since all the constructs interact with each other ([Figure 3D](#fig3){ref-type="fig"}; [Supplementary Figure S3B](#SM1){ref-type="supplementary-material"}).

Taking into account the interactions revealed by the BACTH assay, we propose that the Tle3 toxin can be addressed to the H2-T6SS machinery VgrG2b component via PA0259. We thus named PA0259 "Tla3" for Type VI lipase adaptor protein.

Tla3 (PA0259) Characterization {#sec16}
------------------------------

To gain insight into the role of Tla3 during Tle3 secretion, we first validated the interactions of Tla3 with Tle3 and VgrG2b by a complementary approach of co-purification by affinity chromatography. Two different tagged versions of Tla3 were engineered by fusing a Strep-tag or a 10His-tag to the mature domain of Tla3 this leading to cytoplasmic tagged Tla3 proteins. The recombinant Tla3^C^~Strep~ was coproduced in *E. coli* BL21(DE3) pLysS with Tle3^C^~His~, and the Tla3^C^~His~ with 3 recombinant forms of Strep-tagged VgrG2b consisting in the full-length VgrG2b, or VgrG2b truncated for the extreme C-terminus (deletion of domain 3 in [Figure 3A](#fig3){ref-type="fig"}) or VgrG2b truncated for the extreme C-terminus and the TTR domain (deletion of domains 2 and 3 in [Figure 3A](#fig3){ref-type="fig"}). We initially tried with His-tagged VgrG2b but a problem of protein instability led us to shift for Strep-tagged VgrG2b. The bacterial lysates were loaded on a StrepTactin matrix, and Tla3^C^~Strep~ or the three recombinant VgrG2b~Strep~ were eluted with desthiobiotin. The presence of Tle3^C^~His~ and of Tla3^C^~His~ was visualized in the elution fractions with anti-His antibodies. As shown in [Figures 4A](#fig4){ref-type="fig"}, [2A](#fig2){ref-type="fig"} right panel and [Supplementary Figure S6](#SM1){ref-type="supplementary-material"}, Tle3^C^~His~ was only found in the eluted fraction upon coproduction with Tla3^C^~Strep~. We observed that Tla3^C^~His~ is copurified only upon coproduction with the full length VgrG2b ([Figure 4B](#fig4){ref-type="fig"} and [Supplementary Figure S6](#SM1){ref-type="supplementary-material"}) or the VgrG2b truncated for the extreme C-terminus ([Figure 4C](#fig4){ref-type="fig"} and [Supplementary Figure S6](#SM1){ref-type="supplementary-material"}). Indeed when produced alone ([Figure 4B](#fig4){ref-type="fig"} and [Supplementary Figure S6](#SM1){ref-type="supplementary-material"}) or with VgrG2b truncated for the extreme C-terminus and the TTR domain ([Figure 4D](#fig4){ref-type="fig"} and [Supplementary Figure S6](#SM1){ref-type="supplementary-material"}), Tla3^C^~His~ was not purified by affinity chromatography. Since VgrG2b truncated for the extreme C-terminus still copurified with Tla3 we can exclude that this domain is required for the interaction. This is in line with the BACTH assay that showed an interaction between Tla3 and a truncated VgrG2b consisting in only the DUF2345 and TTR domains (domains 1 and 2, [Figure 3A](#fig3){ref-type="fig"}). Moreover, the deletion of the TTR domain affecting the copurification, one can conclude that this domain is key for the interaction. Taken together these data confirmed a direct interaction of Tla3 with Tle3 on one side and with VgrG2b on the other side. By taking into account the BACTH data and the copurification with two truncated forms of VgrG2b, the domain of interaction of VgrG2b with Tla3 can be delimitated to the TTR domain.

![Tla3 interaction with Tle3 **(A)** and VgrG2b **(B--D)**. Copurification assay on StrepTactin column of Tla3^c^~STREP~ with Tle3^c^~His~ produced *in E. coli* BL21(DE3)pLysS from pBB27 and pVT1, respectively, **(A)** or of Tla3^c^~His~ with VgrG2b^FL^~STREP~ **(B)** or VgrG2b^FLD3^~STREP~ **(C)** ~or~ VgrG2b^FLD2-3^~STREP~ **(D)** produced from pBB28 and pBB25 **(B)** or pBB41**(C)** or pBB42 **(D)**. The unbound (U) and eluted (E) fractions were collected and subjected to SDS-PAGE (10.5%) and Western blot analysis using anti-His antibody (upper) and anti-streptavidin antibody (lower). The dashed line separates lanes from non-adjacent part of the same gel. The position of the proteins and the molecular mass markers (in kDa) are indicated.](fmicb-10-01218-g004){#fig4}

We then analyzed the cellular localization of Tla3 in *P. aeruginosa* that, according to its interactions with Tle3 and VgrG2b, should be cytoplasmic. As for Tli3, we engineered a chromosomally encoded Tla3~V5~ translational fusion ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}). Tla3 was indeed immunodetected in the cytoplasmic fraction ([Figure 5A](#fig5){ref-type="fig"}). One could note that in contrast with our first hypothesis suggesting an incorrect start codon for *tla3* and our observation of the recombinant protein in the periplasm of *E. coli* ([Supplementary Figure S1](#SM1){ref-type="supplementary-material"}), Tla3 was totally absent from the periplasmic fraction of *P. aeruginosa*. To strengthen this result, each putative ATG was individually mutated on the chromosome of the PAO1 strain encoding the Tla3~V5~ translational fusion ([Figure 5B](#fig5){ref-type="fig"}). In agreement with its cytoplasmic localization in *P. aeruginosa*, Tla3 was only produced if the fourth ATG was intact. Accordingly the Tla3 protein synthesized from this ATG is not predicted to possess a N-terminal signal peptide ([Supplementary Figure S1](#SM1){ref-type="supplementary-material"}). In conclusion, Tla3 is a cytoplasmic protein synthesized from the annotated translation start[^1^](#fn001){ref-type="fn"} and this localization is in agreement with a role in the targeting of the toxin to the secretion machinery.

![**(A)** Tla3(PA0259) is a cytoplasmic protein of *P. aeruginosa*. Cells of *P. aeruginosa* PAO1 *tla3~V5~* were subjected to fractionation and immunoblotting using antibodies directed against the V5 tag, XcpY and DsbA. XcpY and DsbA were used as membrane and periplasmic controls, respectively. T, whole cell; C, cytoplasm; Mb, total membrane; P, periplasm. **(B)** The annotated ATG drives the initiation of translation of *tla3* in *P. aeruginosa*. Immunodetection of Tla3~V5~ with anti-V5 antibodies produced in a WT background or in strains in which one of the four predicted ATG in *tla3* have been substituted in ATA. The number followed by a star indicates which ATG from [Supplementary Figure S1](#SM1){ref-type="supplementary-material"} ATG~4~ corresponds to the annotated ATG. **(C)** Tla3 is not required for Hcp2b secretion. Immunodetection of Hcp2b~6His~ with anti-His antibodies produced in a WT background (line 1) or in strains deleted for *rsmA* (lines 2--4) and *clpV2* (line 3) or *tla3* (line 4). The strains were grown at 25°C for 24 h and total bacteria were separated from extracellular medium. Anti-EF-Tu is used as a lysis control. The extracellular medium proteins were also stained with Coomassie-blue. **(D)** Tla3 does not interact with Tle4. Copurification assay on StrepTactin column of Tla3^c^~STREP~ with Tle4~His~ produced *in E. coli* BL21(DE3)pLysS from pBB27 and pVT3 respectively. Legend is as in [Figure 4](#fig4){ref-type="fig"}. **(E)** Tla3 is not secreted. Immunodetection of Tla3~V5~ with anti-HV5 antibodies produced in a WT background (line 1) or in strain deleted for *rsmA* (line 2). The strains were grown at 25°C for 24 h and total bacteria were separated from extracellular medium. Anti-EF-Tu is used as a lysis control. The extracellular medium proteins were also stained with Coomassie-blue. **(A‑E)** The position of the proteins and the molecular mass markers (in kDa) are indicated.](fmicb-10-01218-g005){#fig5}

Next, we asked whether Tla3 is specific for Tle3 or if it can be required for the secretion of other substrates of the H2-T6SS machinery. Since Hcp secretion is the hallmark of a functional secretion system, we studied the secretion of Hcp2b whose gene is upstream *vgrG2b* ([Figure 1A](#fig1){ref-type="fig"}). Like [@ref2], we deleted the *rsmA* gene to enable Hcp2b production and thus secretion by a PAO1 strain encoding a Hcp2b~His~ translational fusion ([Figure 5C](#fig5){ref-type="fig"}, compare lines 1 and 2). RsmA is a posttranscriptional regulator known to repress all three T6SS clusters of *P. aeruginosa* ([@ref2]). This results in a massive secretion since Hcp2b~His~ can be observed in the extracellular protein samples by Coomassie-blue staining ([Figure 5C](#fig5){ref-type="fig"}, lower panel). While Hcp2b~His~ secretion was abolished in a *rsmA clpV2* mutant, a H2-T6SS mutant, we observed that Hcp2b~His~ is still secreted in the absence of Tla3 ([Figure 5C](#fig5){ref-type="fig"}, compare line 3 with line 4), suggesting that Tla3 is specific for the secretion of Tle3 but not for other H2-T6SS proteins. In line with this specific adaptor-toxin pair, Tla3^C^~Strep~ did not copurify TplE (Tle4), another antibacterial phospholipase delivered by the H2-T6SS machinery ([Figure 5D](#fig5){ref-type="fig"} and [Supplementary Figure S6](#SM1){ref-type="supplementary-material"}).

Finally as the interaction with a VgrG can suggest that Tla3 is itself a T6SS effector, we studied whether Tla3 is secreted by *P. aeruginosa*. To this end, the *rsmA* gene was deleted from the PAO1 strain encoding a Tla3~V5~ translational fusion. Whereas Tla3~V5~ was better produced upon *rsmA* deletion ([Figure 5E](#fig5){ref-type="fig"}), this did not lead to immunodetection of Tla3~V5~ in the extracellular medium although Hcp2b was readily observed by Coomassie-blue staining of the same samples. Tla3 is thus not an effector *per se*.

In conclusion, the cytoplasmic localization of Tla3 in *P. aeruginosa* is appropriate with a recruiting role of Tle3 to the H2-T6SS machinery through an interaction with the TTR domain of VgrG2b. Tla3 is not co-secreted with Tle3. Tla3 role seems specific to Tle3 since it is not required for a functional H2-T6SS machinery and does not interact with TplE (Tle4), another H2-T6SS effector.

Tle3 Secretion Mechanism by the H2-T6SS Machinery of *P. aeruginosa* {#sec17}
--------------------------------------------------------------------

In order to study the antibacterial role and the secretion of Tle3 by *P. aeruginosa*, we performed intra-species bacterial competition assays between *P. aeruginosa* strains. This consists in studying the survival of prey bacteria lacking the *tli3* immunity gene (by CFU counting of antibiotic resistant bacteria) co-cultivated 24 hours at 37°C on plate with various attackers. As immunity genes are essential genes (protection from fratricide intoxication), both toxin and immunity genes have been deleted in order to construct a *via*ble Δ*tli3*Δ*tle3* mutant strain ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}). [Figure 6](#fig6){ref-type="fig"} first confirms the antibacterial function of Tle3 and the immunity role of Tli3 since the growth of the immunity mutant was affected by the WT strain because it cannot resist Tle3 toxicity, while the Δ*tle3* mutant had no effect ([Figure 6](#fig6){ref-type="fig"} compare line 1 with line 2). The use of the Δ*clpV2* strain, a H2-T6SS mutant, and of Δ*vgrG2b* and Δ*tla3* mutants allowed to demonstrate that Tle3 is delivered to prey bacteria through the H2-T6SS machinery and confirms that VgrG2b and Tla3 participate in Tle3 targeting to the H2-T6SS machinery ([Figure 6](#fig6){ref-type="fig"} compare line 1 with lines 4, 5, and 6). Indeed Δ*clpV2*, Δ*vgrG2b* and Δ*tla3* mutants had no effect on the immunity mutant growth since they cannot deliver Tle3 into prey bacteria. The complementation *in cis* of *tle3* and *tla3* deletions (the mutants have been constructed for this study) restored a WT phenotype ([Figure 6](#fig6){ref-type="fig"} compare line 2 with line 3, and line 6 with line 7) this demonstrating no polar effect on downstream genes. Furthermore, the introduction of a wild-type copy of *tli3* at the *attB* site on *P. aeruginosa* chromosome of the Δ*tli3*Δ*tle3* mutant restores wild-type competition capacity to this strain ([Supplementary Figure S4A](#SM1){ref-type="supplementary-material"}). This confirms that the absence of the immunity was responsible of the phenotypes observed for the Δ*tli3*Δ*tle3* strain ([Figure 6](#fig6){ref-type="fig"}). Finally, the Δ*tla3* mutant has been used as a prey and was not affected by the WT strain or any of the mutants excluding definitively a role of immunity as proposed by its annotation (see text footnote 1) and confirming its adaptor function ([Supplementary Figure S4B](#SM1){ref-type="supplementary-material"}).

![*P. aeruginosa* growth competition. The *P. aeruginosa* prey strain (Δ*tli3*Δ*tle3*) was incubated with various *P. aeruginosa* attacker strains as indicated in the figure for 24 h at 37°C. The number of recovered prey bacteria is indicated in CFU/ml. "comp" stand for *cis* complementation of the corresponding mutation with a wild-type copy inserted at the *attB* site on *P. aeruginosa* chromosome. Error bars represent ± SEM (*n* = 3); \*\*\**p* \< 0.001, ns not significant.](fmicb-10-01218-g006){#fig6}

Taken together, these results demonstrated that Tle3 is an effective H2-T6SS-dependent antibacterial toxin loaded onto the VgrG2b puncturing device *via* Tla3 and neutralized by Tli3 in resistant prey bacteria.

VgrG2b Is a Trans-Kingdom Toxin {#sec18}
-------------------------------

A putative neutral zinc metallopeptidase domain has been predicted at the extreme C-terminus of VgrG2b by Pukatzki and colleagues ([Figure 3A](#fig3){ref-type="fig"}; [@ref33]). This motif (Prosite PS00142, PFAM04298) consists in a metal-binding consensus motif HExxH, the two histidine residues being ligands of the catalytic Zn^2+^ and the glutamic acid residue involved in nucleophilic attack. As an effector with a protease activity can target both eukaryotic and bacterial proteins, we searched for an antibacterial activity of the VgrG2b C-terminal extension. To do this, we performed the same heterologous toxicity assay in *E. coli* as with Tle3. As shown in [Figure 7](#fig7){ref-type="fig"}, whereas the production of VgrG2b~Cter~ in the cytoplasm did not impact *E. coli* growth, its periplasmic production killed *E. coli* ([Figure 7](#fig7){ref-type="fig"}, compare lines 2 and 5). Moreover substitution of the histidine in position 935 and of the glutamic acid 936 for an alanine relieves VgrG2b~Cter~ toxicity this showing that VgrG2b is a novel antibacterial protease active in the periplasm.

![The protease domain of VgrG2b is required for its antibacterial activity. Serial dilutions (from non-diluted to 10^−5^) of normalized cultures of *E. coli* BL21(DE3)pLys producing the wild-type C-terminal domain of VgrG2b in the cytoplasm, called CterVgrG2b^C^ (from pBB43, a pETDuet-1 derivative, line 5) or in the periplasm, called CterVgrG2b^P^ (from pBB44, a pET22b(+) derivative yielding a fusion of the C-terminal domain with a Sec signal peptide, line 2) or two variants CterVgr2b^P^~H935A~ (from pBB45, line 3) and CterVgr2b^P^~E936A~ (from pBB46, line 4) were spotted on LB agar plates supplemented (left panel) with 0.4% glucose or (right panel) with 0.1 mM IPTG. In line 6, the CterVgrG2b^P^ (from pBB44) was coproduced with Tli3 (from pVT8) and in line 7, the CterVgrG2b^P^ and Tli3 were coproduced from the same transcript (from pSBC110). Glucose and IPTG allow respectively repression and induction of the gene encoding the T7 RNA polymerase.](fmicb-10-01218-g007){#fig7}

Finally because of their genetic proximity, we tested whether Tli3 can be the immunity of VgrG2b~Cter~. Indeed, the coproduction of Tli3 counteracts VgrG2b~Cter~ toxicity whether it is coproduced from a second plasmid ([Figure 7](#fig7){ref-type="fig"}, line 6) or from the same transcript ([Figure 7](#fig7){ref-type="fig"}, line 7). In conclusion Tli3 serves two toxins and protects also from the antibacterial activity of VgrG2b.

Discussion {#sec19}
==========

Here, we report the existence of a novel pair of antibacterial effector and immunity of the H2-T6SS of *P. aeruginosa*, Tle3 (PA0260) and Tli3 (PA0261), and we propose a chronology of Tle3 secretion process that includes a cytoplasmic adaptor protein, Tla3 (PA0259) to load the toxin onto the VgrG2b spike (a model is proposed in [Figure 8](#fig8){ref-type="fig"}). Through heterologous toxicity assay and bacterial competition, we show that Tle3 was toxic once delivered in the periplasm of prey bacteria and that Tli3 can neutralize the toxin in this compartment. Interestingly, this led us to discover that VgrG2b that we previously recognized as an anti-eukaryotic effector possesses an antibacterial activity as well.

![Working model: Tle3 targeting to the H2-T6SS machinery (left panel) Tle3 (in pink) is taken in charge in the cytoplasm by Tla3 (in orange) that binds VgrG2b (green). Upon Hcp2b (in dark grey) assembly into the growing sheath (light grey), the VgrG2b loaded with the Tle3 is placed at the tip of the Hcp arrow. Tle3 and VgrG2b~Cter~ delivery into bacteria (right panel). The sheath contraction in the cytoplasm propels the Hcp arrow towards the target bacterium. Tle3 associated with this expelled structure is thus translocated into target cells, as well as VgrG2b~Cter~ (green circle). The prey is killed (Prey^S^) except if it has the Tli3 immunity (in blue) in the periplasm (Prey^R^). The mechanism of resistance to VgrG2b~Cter~ is still unknown. OM, outer membrane; PG, peptidoglycan; IM, inner membrane; BP, base plate; MC, membrane complex. Prey^S^, sensitive prey; Prey^R^, resistant prey.](fmicb-10-01218-g008){#fig8}

The VgrG-recruitment of cargo effectors has been previously evidenced for several antibacterial effectors among them two toxins of the Tle family, TseL (Tle2) of *V. cholerae* ([@ref13]; [@ref25]; [@ref42]) and Tle1 of EAEC ([@ref14]). In both cases, the *tle* genes were just downstream the *vgrG* genes like the organization of *vgrG2b* and *tle3* of *P. aeruginosa*. TseL and Tle1 have been shown to directly bind a dedicated VgrG, VgrG3 and VgrG1 respectively ([@ref13]; [@ref14]). The domain of interaction within EAEC VgrG1 has been delimitated to the TTR domain and may also include the DUF2345, both of which are present in the *P. aeruginosa* VgrG2b. In line with this, and despite Tle3 requiring an adaptor to be targeted to VgrG2b, we have shown that Tla3 interacts with the TTR domain of VgrG2b. Taken together these data demonstrate that TTR domains of VgrGs are involved in recruitment and transport of Tle effectors, directly or through adaptor. Likewise, C-terminal extensions of VgrG1 and VgrG2 of *Agrobacterium tumefaciens* were identified as specifically required for the delivery of each cognate DNAse toxins, named Tde1 and Tde2, respectively ([@ref8]). C-terminal domains of VgrGs can thus be considered more generally as specificity determinants for T6SS effector loading and transport.

Interestingly, TseL of *V. cholerae* requires also Tap-1 (Tec) as an adaptor protein to be delivered to another VgrG, called VgrG1 ([@ref25]; [@ref42]), showing that a sole toxin can be targeted directly and indirectly to two different VgrG proteins. Tap-1 (Tec) belongs to the DUF4123 family of adaptor proteins that contains also VasW of *V. cholerae* ([@ref29]) and several uncharacterized gene products linked to effector genes with a MIX (marker for type VI effectors) motif in *Proteus mirabilis* or *B. thailandensis* for instance ([@ref36]). Interestingly TecT, a DUF4123 adaptor of *P. aeruginosa*, has been shown to require a co-adaptor, called co-TecT, to deliver the TseT effector to the PAAR4 protein ([@ref9]). This is the first example of an adaptor-co-adaptor module. Taken together, these data suggest a conserved role for DUF4123 adaptors in the recruitment of a number of T6SS effectors. Remarkably Tla3 of *P. aeruginosa* does not belong to the DUF4123 adaptor family, or to that of the two other unrelated families, the DUF1795 adaptor family, reported with EagR (effector-associated gene with Rhs) in *Serratia marcescens* ([@ref1]) or EagT6 in *P. aeruginosa* ([@ref44]), and the DUF2169 adaptor family reported with Atu3641 in *A. tumefaciens* ([@ref8]). Nor Tla3 is a PAAR protein, the last class of effector targeting mode to a VgrG ([@ref41]; [@ref43]; [@ref8]; [@ref11]; [@ref9]). Instead, we find that Tla3 harbors two DUF2875 domains ([Figure 3A](#fig3){ref-type="fig"}) that are both required for the interaction with the toxin. Moreover, genes coding DUF2875 containing proteins can be find at the vicinity of *tle*, *tli*, *vgrG*, or PAAR genes, but they are restricted to α and β proteobacteria ([Supplementary Figure S5](#SM1){ref-type="supplementary-material"}). We thus hypothesize that DUF2875 might assist in T6SS-mediated effector delivery. Like the three other adaptor families (DUF4123, DUF1795, and DUF2169), we have observed that Tla3 is not required for the H2-T6SS functionality since the Δ*tla3* mutant still secrete Hcp2b and can compete with a WT strain, and that Tla3 is specific for the Tle3 toxin since it did not interact with another H2-T6SS effector, TplE (Tle4). Finally, as we did not detect Tla3 secretion under constitutive H2-T6SS condition, we propose that Tla3 hands over Tle3 to VgrG2b in the cytoplasm prior to its loading to the baseplate and further recruitment to the central Hcp tube in preparation ([Figure 8](#fig8){ref-type="fig"}). Overall, the existence of various modes of effector recruitment, further refined with adaptors, likely explains how the T6SS is able to deliver numerous and structurally diverse proteins.

Five families of Tle, Tle1--5, have been identified among Gram-negative bacteria ([@ref35]) and four Tle have been studied in *P. aeruginosa* so far. Our demonstration of the activity of Tle3 in the periplasm is consistent with the observations that the heterologous periplasmic production of PldA (Tle5a) ([@ref35]; [@ref21]), PldB (Tle5b) ([@ref21]), Tle1 ([@ref17]), and TplE (Tle4) ([@ref20]) is toxic. The reason of the periplasmic activity of Tle proteins is still unclear although several hypothesis have been proposed ([@ref14]), the most likely being an activation of the toxin in this compartment. Very recently this has nicely been exemplified with the hijacking of DsbA in the target cells of *S. marcescens* for the activation of incoming effectors ([@ref28]). No member of the Tle3 family has yet been enzymatically characterized. Our attempts to efficiently purify Tle3 from *E. coli* or from *P. aeruginosa* have been unsuccessful, even if we have noticed that the presence of the Tla3 adaptor stabilized Tle3, it still formed inclusion bodies. In the future, we will decipher the enzymatic activity of Tle3, which is presumably active on membrane phospholipids as our preliminary data of thin-layer chromatography tend to show.

The periplasmic activity of Tle toxins is counteracted by the synthesis of a cognate immunity protein that is usually a periplasmic soluble protein, as we showed for Tli3 in *P. aeruginosa*, or a membrane-anchored lipoprotein ([@ref35]). Interestingly the genetic organization of the *tli3* gene upstream of the *tle3* gene observed in *E. coli*, *K. pneumoniae*, *B. cenocepacia*, or *R. solanacearum* ([@ref35]) is conserved in *P. aeruginosa*. The fact that the two genes are co-transcribed (the immunity being the first) is key for the protection against toxicity. Indeed, we have observed systematic protection against the periplasmic toxicity of Tle3 in *E. coli* when the two genes were expressed from the same promoter under the same plasmid, whereas it was not as efficient when the genes were on two plasmids. This genetic link reinforces the connection within the toxin/immunity pair. This has previously been noticed with a T7SS antibacterial toxin and its immunity in *Staphylococcus aureus* ([@ref10]). Other immunities of Tle characterized so far have been shown to inhibit the action of the effector by direct protein-protein contacts ([@ref35]; [@ref21]; [@ref14]). Our copurification assay in *E. coli* demonstrates a direct interaction between Tle3 and Tli3 that was already suggested with the release of Tle3 toxicity upon coproduction of Tli3 in the periplasm. A crystal structure of the *P. aeruginosa* TplE (Tle4) effector in complex with its immunity protein TplEI (Tli4) revealed that the immunity uses a grasp mechanism to prevent the interfacial activation of the toxin ([@ref26]).

Like two other H2-T6SS-related orphan *vgrG* loci, the *vgrG4b* cluster encoding PldA (Tle5a) and the *vgrG2a* encoding TplE (Tle4), we show here that the *vgrG2b* cluster has both antibacterial activities (through Tle3 and VgrG2b) and anti-eukaryotic (through VgrG2b; [@ref37]). Interestingly, VgrG2b is thus (1) a structural component of the H2-T6SS puncturing device since our bacterial competition showed its requirement for Tle3 delivery, (2) an anti-eukaryotic effector through an interaction with the microtubule nucleating complex ([@ref37]), and (3) an antibacterial effector as suggested by our toxicity assay in *E. coli*. We have shown that two conserved residues of the putative metallopeptidase motif (a histidine and a glutamic acid) are essential for the VgrG2b antibacterial activity. This is consistent with an antibacterial protease activity for VgrG2b that will be, to our knowledge, the first case in the T6SS effector literature. The discovery of the VgrG2b immunity is even more exciting since we observed that Tli3 also relieves VgrG2b~Cter~ toxicity. To our knowledge, Tli3 is the first example of a T6SS immunity serving two different proteins. But one can cite the chaperones of the type III secretion translocators that form a pore in the eukaryotic target cell membrane ([@ref31]). Indeed the chaperone SycD from *Yersinia* enterocolitica and its homologues from other Gram-negative bacteria bind the two translocators to prevent their premature interaction in the inner membrane and avoid further toxicity.
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